Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Nateraâs complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications. Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Companyâs own robust laboratory processes thousands of genetic tests per month. Nateraâs goal is to transform the way people â both providers and patients â respond to and manage genetic diseases. Source
No articles found.
CTI BioPharma is a biopharmaceutical company focused on the acquisition, developme...
CTI BioPharma is a biopharmaceutical company fo...
Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthro...
Eyenovia is a late-stage ophthalmic biopharmace...
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of h...
Bio-Techne Corporation (NASDAQ: TECH) is a lead...
Precipio has built a platform designed to eradicate the problem of misdiagnosis by...
Precipio has built a platform designed to eradi...
SINTX Technologies is a commercial biomaterial company focused on using its silico...
SINTX Technologies is a commercial biomaterial ...
Together, a potent new drug and a blood test to guide its use can be a life change...
Together, a potent new drug and a blood test to...
Developing flexible and affordable genetic testing that improves the everyday live...
Developing flexible and affordable genetic test...
Join the National Investor Network and get the latest information with your interests in mind.